Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20241226005
- Term of Validity
- 26 December 2024 - 26 December 2025
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Spanish research team specialized in the field of biotechnology, has developed and patented a murine extracellular 3D matrix generated from an immortalized cell line obtained from embryonic epicardium (EPIC) that can be used as an acellular support for eukaryotic cell cultures alone or in combination with gelatins and compatible acellular supports. A company willing to implement and commercialize the technology through a license agreement or a technical agreement is sought
- Full Description
-
Some of the activities carried out by the research group are focused on the field of cardiovascular development and angiogenesis. The present invention proposes a murine extracellular matrix (ECM) secreted by a cell line of epicardium origin that shows native structural and molecular properties and a better capacity to retain circulating cells than other commercial immortalized cell lines.
Backgroud: Some eukaryotic cells require supports to grow and generate an in vitro environment more similar to that in vivo. Said supports can be cellular or acellular.
On the one hand, the use of cell supports cannot specifically control either the composition of the culture medium or the growth dynamics of the support cells. On the other hand, acellular supports only partially reproduce biological 3D structures, and some even show limitations in terms of biocompatibility.
Currently the main limitation of acellular supports is their lack of similarity with natural extracellular matrices at the level of structure and composition. In addition, they have laborious synthesis protocols, which makes the product quite expensive.
The proposed invention arises as a solution to this problem and consists of a murine extracellular 3D matrix generated from an immortalized cell line obtained from embryonic epicardium (EPIC). This matrix retains structure, composition and natural properties very similar to both the embryonic and adult cardiac extracellular matrix, and can be used as an acellular support for eukaryotic cell cultures alone or in combination with gelatins and compatible acellular supports, such as the gelatin.
Thus, there is a need in the present technical field to develop supports to grow and generate an in vitro environment more similar to that in vivo, but overcoming the difficulties mentioned above.
Companies in the biotechnology sector that wish to implement and commercialize the technology via license agreement or want to explore the new possibilities in the field of cell culture through technical agreement are sought - Advantages and Innovations
- Compared to existing supports, the newly developed support generates a biocompatible three-dimensional structure of animal origin. These characteristics give it demonstrable advantages compared to other acellular supports since it helps improve the growth and proliferation of different cell types, such as endothelial cells. Furthermore, the technical procedures for its synthesis and isolation are more economical than those currently used for those offered on the market. Finally, it should be noted that, as it is synthesized from an immortalized cell line, the variability between different production batches is reduced and the sacrifice of animals is not required to obtain it.
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- A Wordwide (PCT countries) protection application.
Partner Sought
- Expected Role of a Partner
-
Type: The team is looking for industrial partners interested in implementing and commercializing the technology worldwide. Companies that want to enter into a licensing agreement or alternatively technical agreement, in order to explore the new possibilities in the biotechnology sector are sought.
Role of partner: companies that wish to obtain patent rights as a licensee to implement and commercialize the technology at international level. - Type and Size of Partner
- SME 50 - 249
- SME 11-49
- Big company
- SME <=10
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05003006 - Other therapeutic (including defibrillators)
- 04008 - Genetic Engineering
- 04006 - Cellular and Molecular Biology
- 04009 - In vitro Testing, Trials
- Sector Groups Involved
- Health
- Targeted countries
- All countries